Detalhe da pesquisa
1.
Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
Eur J Cancer Care (Engl)
; 29(4): e13253, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32578279
2.
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial.
Clin Cancer Res
; 26(22): 5820-5829, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32938620
3.
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).
Breast
; 54: 286-292, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33242755